StartsideTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
Forrige sluttkurs
4,31 $
Dagsintervall
4,33 $ - 4,40 $
Årsintervall
3,03 $ - 14,80 $
Markedsverdi
5,85 mill. USD
Gjennomsnittlig volum
47,43k
P/E-tall
-
Utbytte
-
Hovedbørs
NASDAQ
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
| (USD) | mars 2025info | Endring år til år |
|---|---|---|
Omsetning | — | — |
Driftskostnader | 534,00k | −49,76 % |
Nettoomsetning | −563,00k | 46,89 % |
Netto resultatmargin | — | — |
Fortjeneste per aksje | — | — |
EBITDA | −532,75k | 49,79 % |
Faktisk avgiftssats | — | — |
Balanseregnskap
Totale aktiva
Totale passiva
| (USD) | mars 2025info | Endring år til år |
|---|---|---|
Kontant / kortsiktige inv. | 1,94 mill. | −68,42 % |
Totale aktiva | 2,16 mill. | −67,56 % |
Totale passiva | 279,00k | −50,09 % |
Total egenkapital | 1,88 mill. | — |
Utestående aksjer | 914,23k | — |
P/B-forhold | 2,10 | — |
Avkastning på aktiva | −52,57 % | — |
Avkastning på kapital | −61,85 % | — |
Kontantstrøm
Netto kontantstrøm
| (USD) | mars 2025info | Endring år til år |
|---|---|---|
Nettoomsetning | −563,00k | 46,89 % |
Kontantstrøm fra drift | −867,00k | −41,44 % |
Kontanter fra investering | — | — |
Kontanter fra finansiering | −19,00k | — |
Netto kontantstrøm | −886,00k | −44,54 % |
Fri kontantstrøm | −656,75k | −213,67 % |
Om
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Grunnlagt
1991
Hovedkvarter
Nettsted
Ansatte
4
